ArticleInternational journal of women's health2026
Management Strategies for Aromatase Inhibitor-Associated Musculoskeletal Symptoms and Their Impact on Treatment Persistence in Postmenopausal Breast Cancer: A Single-Center Retrospective Cohort Study.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) frequently lead to discontinuation of adjuvant endocrine therapy in postmenopausal breast cancer (BC) patients. This retrospective study assessed the impact of initial combined versus monotherapy management on aromatase inhibitor (AI) treatment persistence and explored whether baseline pain interference moderates this effect. Methods: In this single-center, retrospective cohort study of 253 postmenopausal hormone receptor-positive BC patients with AIMSS, Patients were categorized into the monotherapy group (n = 182) or the combined therapy group (n = 71) based on initial management. Combined therapy was defined as the simultaneous use of ≥2 different categories of management interventions initiated at the time of AIMSS diagnosis (eg, analgesics, physical therapy, or AI regimen adjustment). The primary outcome was treatment interruption-free survival. Kaplan-Meier and Cox regression analyses were conducted to test for an interaction between management strategy and baseline Brief Pain Inventory (BPI) interference score (high: ≥ 7; low: < 7). Results: Treatment interruptions occurred in 68 (26.9%) patients. Combined therapy was associated with superior interruption-free survival (Log-rank Conclusion: Initiating multimodal combination management for AIMSS patients with severe baseline pain interference significantly improves AI treatment persistence and provides greater short-term symptom relief, supporting stratified management based on symptom severity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.